Dermapharm Holding SE (XETRA:DMP) — Market Cap & Net Worth
Market Cap & Net Worth: Dermapharm Holding SE (DMP)
Dermapharm Holding SE (XETRA:DMP) has a market capitalization of $2.29 Billion (€1.96 Billion) as of June 17, 2026. Listed on the XETRA stock exchange, this Germany-based company holds position #5883 globally and #895 in its home market, demonstrating a 2.45% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Dermapharm Holding SE's stock price €48.15 by its total outstanding shares 49540810 (49.54 Million). Review Dermapharm Holding SE debt and liabilities to assess the company's total debt and financial obligations.
Dermapharm Holding SE Market Cap History: 2018 to 2026
Dermapharm Holding SE's market capitalization history from 2018 to 2026. Data shows growth from $1.11 Billion to $2.79 Billion (9.89% CAGR).
Index Memberships
Dermapharm Holding SE is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
GEX (GERMAN ENTREPRENEURIAL TOTAL RETURN INDEX)
GEX
|
$7.22 Billion | 31.77% | #2 of 9 |
Weight: Dermapharm Holding SE's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Dermapharm Holding SE Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Dermapharm Holding SE's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.96x
Dermapharm Holding SE's market cap is 1.96 times its annual revenue
Latest Price to Earnings (P/E) Ratio
17.21x
Dermapharm Holding SE's market cap is 17.21 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $1.11 Billion | $572.42 Million | $75.32 Million | 1.94x | 14.71x |
| 2019 | $1.99 Billion | $700.88 Million | $77.20 Million | 2.84x | 25.75x |
| 2020 | $2.90 Billion | $793.83 Million | $85.83 Million | 3.65x | 33.80x |
| 2021 | $4.61 Billion | $942.91 Million | $209.58 Million | 4.89x | 21.98x |
| 2022 | $2.03 Billion | $1.02 Billion | $134.24 Million | 1.98x | 15.09x |
| 2023 | $2.34 Billion | $1.14 Billion | $62.37 Million | 2.06x | 37.49x |
| 2024 | $2.25 Billion | $1.18 Billion | $113.79 Million | 1.91x | 19.80x |
| 2025 | $2.28 Billion | $1.16 Billion | $132.41 Million | 1.96x | 17.21x |
Competitor Companies of DMP by Market Capitalization
Companies near Dermapharm Holding SE in the global market cap rankings as of June 17, 2026.
Key companies related to Dermapharm Holding SE by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #513 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #561 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #624 globally with a market cap of $44.20 Billion USD ( CN¥302.05 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #513 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #561 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.22 |
| #624 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $44.20 Billion | CN¥47.35 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.60 |
Dermapharm Holding SE Historical Marketcap From 2018 to 2026
Between 2018 and today, Dermapharm Holding SE's market cap moved from $1.11 Billion to $ 2.79 Billion, with a yearly change of 9.89%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €2.79 Billion | +22.36% |
| 2025 | €2.28 Billion | +1.16% |
| 2024 | €2.25 Billion | -3.65% |
| 2023 | €2.34 Billion | +15.41% |
| 2022 | €2.03 Billion | -56.02% |
| 2021 | €4.61 Billion | +58.80% |
| 2020 | €2.90 Billion | +45.92% |
| 2019 | €1.99 Billion | +79.46% |
| 2018 | €1.11 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Dermapharm Holding SE was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.29 Billion USD |
| MoneyControl | $2.29 Billion USD |
| MarketWatch | $2.29 Billion USD |
| marketcap.company | $2.29 Billion USD |
| Reuters | $2.29 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Dermapharm Holding SE
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, Italy, France, Austria, Switzerland, Spain, Portugal, the Netherlands, Croatia, Poland, Ukraine, the United States, and China. The company operates through three segments: Branded Pharmaceuticals; Other Healthcare Products; and Parallel Import Business. It offers br… Read more